Description
An agonist of IP2, DP2, and EP2 receptors; binds selectively to IP2, DP2, and EP2 over EP1, EP3, and EP4 receptors (Kis = 32, 4.4, 3.6, 212, 2,505, and 826 nM, respectively, in radioligand binding assays); inhibits LPS-induced production of TNF-α, IL-1β, IL-6, and GM-CSF in in isolated human alveolar macrophages at 200 ng/ml; relaxes isolated small pulmonary arteries and veins precontracted with U-46619; reduces right ventricular systolic pressure compared to hypoxic and sham control animals in a mouse model of chronic hypoxic pulmonary hypertension
Formal name: 2-[[(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]-acetic acid, diethanolamine salt
Synonyms: Treprostinil diolamine|UT 15C
Molecular weight: 495.7
CAS: 830354-48-8
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Lipids|Prostaglandins||Product Type|Biochemicals|Receptor Pharmacology|Agonists||Product Type|Biochemicals|Small Molecule Inhibitors|TNF-α/NF-κB Signaling||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Cardiovascular System|Vasculature|Vasodilation||Research Area|Cell Biology|Cell Signaling|NF-κB Signaling||Research Area|Epigenetics, Transcription, & Translation|Transcription Factors||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Lipid Biochemistry|Cyclooxygenase Pathway
